Finance

Lists
Q3 2026 earnings • released • Revenue beat +11.84%
See results
EVT:ETR
Evotec SE
€3.11
+0.52%
(+0.016) 1D
Nov 6, 12:26:04 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for EVT...
Open
€3.09
High
€3.15
Low
€3.03
Mkt. cap
552.30M
Avg. vol.
1.20M
Volume
413.95K
52-wk high
€6.73
52-wk low
€2.41
EPS
-€1.11
Shares outstanding
177.91M
No. of employees
4K
Open
€3.09
High
€3.15
Low
€3.03
Mkt. cap
552.30M
Avg. vol.
1.20M
Volume
413.95K
52-wk high
€6.73
52-wk low
€2.41
EPS
-€1.11
Shares outstanding
177.91M
No. of employees
4K
News stories
From web sources and news partners
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
About Evotec SE
CEO-
Employees4.46K
Founded1993
Headquarters-
SectorHealth Care
Industry-
Websiteevotec.com
Last report
Nov 5, 2026
Fiscal period
Q3 2026
- / -
Revenue / Est. (EUR)
164.93M / 147.46M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
163.89M
253.27M
156.64M
143.48M
Cost of goods sold
163.95M
174.81M
158.21M
145.06M
Cost of revenue
163.95M
174.81M
158.21M
145.06M
Research and development expenses
8.71M
9.83M
10.08M
10.26M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42.31M
44.35M
43.79M
39.29M
Operating expense
43.53M
55.25M
44.85M
87.74M
Total operating expenses
207.48M
230.06M
203.07M
232.80M
Operating income
-43.59M
23.21M
-46.42M
-89.32M
Other non operating income
1.19M
-33.96M
1.89M
-839.00K
EBT including unusual items
-42.96M
29.46M
-122.18M
-48.12M
EBT excluding unusual items
-43.36M
18.35M
-47.40M
-94.00M
Income tax expense
127.00K
14.84M
-244.00K
-1.47M
Effective tax rate
-0.30%
50.37%
0.20%
3.06%
Other operating expenses
-7.50M
1.07M
-9.02M
38.20M
Net income
-43.09M
14.62M
-121.94M
-46.65M
Net profit margin
-26.29%
5.77%
-77.84%
-32.51%
Earnings per share
-0.24
-
-
-
Interest and investment income
841.00K
11.84M
-
-
Interest expense
-2.28M
-
-2.58M
-2.97M
Net interest expenses
-1.44M
11.84M
-2.58M
-2.97M
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.27M
41.91M
-22.60M
-64.88M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps